

associated with becoming physically active and whether environmental factors affect possible benefits.

Becoming physically active is a lifestyle behavior that is influenced by many variables such as socioeconomic status, cultural influences, age, and health status. There is a need to understand how such variables influence the adoption of this behavior by various population groups including children, adolescents, adults, the elderly, and minority populations. Various intervention strategies might be more or less useful for encouraging individuals to adopt and comply with a physically active lifestyle. Different environments such as schools, work sites, health care settings, and family structures need to be examined for their role in promoting physical activity. In addition, costs and availability of adequate resources can influence the adoption of a physically active lifestyle.

The conference will bring together specialists in cardiology, exercise physiology, cardiovascular and behavioral medicine, epidemiology, nutrition, family practice, physical therapy, and nursing as well as representatives from the public on Physical Fitness and Sports.

Advance information on the conference program and conference registration materials may be obtained from: Debra DeBose, Technical Resources International, Inc., 3202 Tower Oaks Blvd., Suite 200, Rockville, Maryland 20852, (301) 770-3153, ddebose@tech-res.com.

The consensus statement will be submitted for publication in professional journals and other publications. In addition, the statement will be available beginning December 20, 1995 from the NIH Consensus Program Information Service, P.O. Box 2577, Kensington, Maryland 20891, phone 1-800-NIH-OMAR (1-800-644-6627).

Dated: November 29, 1995.

Ruth L. Kirschstein,
Deputy Director, NIH.

[FR Doc. 95-30006 Filed 12-8-95; 8:45 am]

BILLING CODE 4140-01-M

Prospective Grant of Exclusive License: Antibacterial Therapy With Bacteriophage Genotypically Modified to Delay Inactivation by the Host Defense System

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the inventions embodied in U.S. Patent Application 08/222,956 and corresponding foreign patent applications entitled, "Antibacterial Therapy with Bacteriophage Genotypically Modified to Delay Inactivation by the Host Defense System" to Exponential Therapies, Inc., New York, New York 10001. The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Alternatively, the subject technology may be licensed as a CRADA invention under 15 U.S.C. 3701 *et seq.* if it is determined to have been made in whole or in part under CRADA 94/0023.

The patent application concerns bacteriophage therapy and discloses methods that enable bacteriophage to delay inactivation by any and all parts of the host defense system (HDS) against foreign objects that would tend to reduce the numbers of bacteriophage and/or the efficiency of those phage at killing the host bacteria present during an infection. The application discloses two methods for producing genotypically modified bacteriophage: (1) Selection by serial passaging and (2) genetic engineering. The foregoing methods can be used to manufacture a variety of distinct therapeutics for antibiotic-resistant bacterial diseases.

ADDRESSES: Requests for copies of the patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Girish C. Barua, Ph.D., Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7735 ext. 263; facsimile: 301/402-0220. A signed Confidentiality Agreement will be required to receive copies of the patent applications. Applications for a license in the indicated exclusive field(s) of use filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a

license which are received by NIH on or before February 9, 1996 will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: December 1, 1995.

Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.

[FR Doc. 95-30003 Filed 12-8-95; 8:45 am]

BILLING CODE 4140-01-M@

Prospective Grant of Exclusive License: Activity Dependent Neurotropic Factor

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the inventions embodied in U.S. Patent Applications 07/688,087, 07/871,973 and 08/324,297 and corresponding foreign patent applications entitled, "Activity Dependent Neurotropic Factor" to Pfizer Inc. of New York, NY. The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The present patent applications cover a purified non-neuronal activity-dependent neurotropic factor (ADNF) protein that increases the growth and survival of developing spinal cord neurons and prevents neuronal cell death. It may have extensive use in treating various neurological deficiencies, such as Alzheimer's disease, Huntington's disease, diabetic neuropathy, spinal cord injury, HIV encephalopathy and stroke.

ADDRESSES: Requests for copies of the patent applications, inquiries, comments and other materials relating to the contemplated licenses should be directed to: Girish C. Barua, Ph.D.,

Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: (301) 496-7735 ext. 263; facsimile: (301) 402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated licenses.

Only written comments and/or applications for a license which are received by NIH on or before February 9, 1996 will be considered. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: November 28, 1995.

Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.

[FR Doc. 95-30005 Filed 12-8-95; 8:45 am]

BILLING CODE 4140-01-M

Public Health Service

National Institutes of Health; Statement of Organization, Functions, and Delegations of Authority

Part H, Chapter HN (National Institutes of Health) (NIH) of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services (40 FR 22859, May 27, 1975, as amended most recently at 60 FR 50634, September 29, 1995), is amended to reflect a technical correction in the title and functional statement of the organization currently identified as the Office of Contracts and Grants Management, Office of Administration, Office of the Director, NIH (OCGM/OA/OD/NIH) (HNAB2). The correct title of this organization is the Office of Contracts Management.

Section HN-B, Organization and Functions, is amended as follows:

Under the heading Office of the Director (HNA), Office of Administration (HNAB), Office of Contracts and Grants Management (HNAB2), delete the title and functional statement in their entirety and substitute the following:

Office of Contracts Management (HNAB2)

(1) Advises the NIH Director and staff and provides leadership and direction for the NIH acquisition activities; (2)

plans, develops and implements NIH-wide contracting policies and procedures and participates with other offices in the Office of the Director, NIH, and with the NIH awarding components in the coordination and implementation of Federal and Departmental acquisition policies and procedures; (3) plans, negotiates, awards, administers, and closes research and development and related contracts for those NIH Institutes, Centers, and Divisions (ICDs) electing to employ this centralized service and advises the Directors of those ICDs on research and development contracting issues; (4) maintains continuing reviews and evaluations of NIH contracting and purchasing operations to ensure adherence to the Federal Acquisition Regulation and all supplemental departmental and NIH policies and standards; (5) provides NIH grants and contracts operating offices with cost/price analysis services and technical advice on the adequacy of accounting systems and financial responsibility of prospective contractors and grantees; negotiates indirect cost rates with commercial organizations awarded contracts or grants; maintains liaison with the Office of the Inspector General, Office of Audit Services, and resolves findings in external audit reports; (6) plans, develops, and directs an NIH-wide Small Business Program in order to maximize contract and purchasing opportunities for small, disadvantaged, and women-owned businesses, and to monitor for compliance with applicable statutes and regulations; (7) analyzes and coordinates requirements for contract information relevant to the NIH IMPAC and higher-level contract data systems for the NIH; (8) analyzes, develops, and coordinates with appropriate departmental and NIH officials on initiatives pertaining to contract automated data and documentation systems, procurement planning and control, contract forms management and contract closure; and (9) manages the NIH acquisition training and certification activities under the Department's Acquisition Training and Certification Program; sponsors other professional acquisition training to attract, develop, and retain high quality personnel; and determines course equivalencies and grants waivers as necessary for employees who serve as project officers on contracts.

Dated: November 30, 1995.

Ruth L. Kirschstein,

Acting Director, NIH.

[FR Doc. 95-30002 Filed 12-8-95; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[AK-962-1410-00-P; F-14954-A2, F-19148-37]

Alaska Native Claims Selection

In accordance with Departmental regulation 43 CFR 2650.7(d), notice is hereby given that a decision to issue conveyance under the provisions of Sec. 14(a) of the Alaska Native Claims Settlement Act of December 18, 1971, 43 U.S.C. 1601, 1613(a), will be issued to Olgoonik Corporation for 13,497 acres. The lands involved are in the vicinity of Wainwright, Alaska, within Tps. 14 and 16 N., Rs. 30 W., Umiat Meridian, Alaska.

A notice of the decision will be published once a week, for four (4) consecutive weeks, in The Arctic Sounder. Copies of the decision may be obtained by contacting the Alaska State Office of the Bureau of Land Management, 222 West Seventh Avenue, #13, Anchorage, Alaska 99513-7599 ((907) 271-5960).

Any party claiming a property interest which is adversely affected by the decision, an agency of the Federal government or regional corporation, shall have until January 10, 1996 to file an appeal. However, parties receiving service by certified mail shall have 30 days from the date of receipt to file an appeal. Appeals must be filed in the Bureau of Land Management at the address identified above, where the requirements for filing an appeal may be obtained. Parties who do not file an appeal in accordance with the requirements of 43 CFR Part 4, Subpart E, shall be deemed to have waived their rights.

Carolyn A. Bailey,

Land Law Examiner, Branch of Gulf Rim Adjudication.

[FR Doc. 95-30060 Filed 12-8-95; 8:45 am]

BILLING CODE 4310-JA-P

[OR-110-1220; G5-205]

Notice Rescinding Emergency Closure and Restriction on Public Lands Near West Fork of Williams Creek

AGENCY: Bureau of Land Management, Medford District, Grants Pass Resource Area, Interior.

ACTION: Public notice.

SUMMARY: The notice published on page 45489 in the issue of Thursday, August 31, 1995, closing entry to and prohibiting physical presence upon all lands, roads and trails near West Fork